Enhanced oncolytic activities of the telomerase-specific replication-competent adenovirus expressing short-hairpin RNA against dicer

Molecular Cancer Therapeutics

Volumn 16, Issue 1, 2017, Pages 251-259

  Machitani, Mitsuhiro ^a,b   Sakurai, Fuminori ^a   Wakabayashi, Keisaku ^a   Tachibana, Masashi ^a   Fujiwara, Toshiyoshi ^c   Mizuguchi, Hiroyuki ^a,d  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; ONCOLYTIC ADENOVIRUS; SHORT HAIRPIN RNA; SMALL UNTRANSLATED RNA; TELOMERASE SPECIFIC REPLICATION COMPETENT ADENOVIRUS; UNCLASSIFIED DRUG; VIRUS RNA; ONCOLYTIC VIRUS; RIBONUCLEASE III; SMALL INTERFERING RNA; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DRUG POTENCY; E1 GENE; FEMALE; GENE CASSETTE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS GENE; VIRUS REPLICATION; WILD TYPE; ADENOVIRIDAE; ANIMAL; ANTIBODY SPECIFICITY; DISEASE MODEL; DRUG SCREENING; GENE ORDER; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; ONCOLYTIC VIROTHERAPY; PROCEDURES; TUMOR CELL LINE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; ORGAN SPECIFICITY; RIBONUCLEASE III; RNA, SMALL INTERFERING; TELOMERASE; TRANSDUCTION, GENETIC; TUMOR BURDEN; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85010041639     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0383     Document Type: Article

References (37)

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70.
2. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2014;12:23-34.
3. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015;33:2780-8.
4. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010;18:243-50.
5. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Curr Pharm Biotechnol 2012;13:1750-60.
6. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62:6165-71.
7. Mathews MB, Shenk T. Adenovirus virus-associated RNA and translation control. J Virol 1991;65:5657-62.
8. Machitani M, Yamaguchi T, Shimizu K, Sakurai F, Katayama K, Kawabata K, et al. Adenovirus vector-derived VA-RNA-mediated innate immune responses. Pharmaceutics 2011;3:338-53.
9. Kitajewski J, Schneider RJ, Safer B, Munemitsu SM, Samuel CE, Thimmappaya B, et al. Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell 1986;45:195-200.
10. Machitani M, Katayama K, Sakurai F, Matsui H, Yamaguchi T, Suzuki T, et al. Development of an adenovirus vector lacking the expression of virus-associated RNAs. J Control Release 2011;154:285-9.
11. O'Malley RP, Mariano TM, Siekierka J, Mathews MB. A mechanism for the control of protein synthesis by adenovirus VA RNAI. Cell 1986;44:391-400.
12. Sano M, Kato Y, Taira K. Sequence-specific interference by small RNAs derived from adenovirus VAI RNA. FEBS Lett 2006;580:1553-64.
13. Lu S, Cullen BR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol 2004;78:12868-76.
14. Xu N, Segerman B, Zhou X, Akusjarvi G. Adenovirus virus-associated RNAII-derived small RNAs are efficiently incorporated into the rna-induced silencing complex and associate with polyribosomes. J Virol 2007;81:10540-9.
15. Andersson MG, Haasnoot PC, Xu N, Berenjian S, Berkhout B, Akusjarvi G. Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 2005;79:9556-65.
16. Aparicio O, Carnero E, Abad X, Razquin N, Guruceaga E, Segura V, et al. Adenovirus VA RNA-derived miRNAs target cellular genes involved in cell growth, gene expression and DNA repair. Nucleic Acids Res 2010;38:750-63.
17. Aparicio O, Razquin N, Zaratiegui M, Narvaiza I, Fortes P. Adenovirus virus-associated RNA is processed to functional interfering RNAs involved in virus production. J Virol 2006;80:1376-84.
18. Machitani M, Sakurai F, Wakabayashi K, Tomita K, Tachibana M, Mizuguchi H. Dicer functions as an antiviral system against human adenoviruses via cleavage of adenovirus-encoded noncoding RNA. Sci Rep 2016;6:27598.
19. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-92.
20. Sugio K, Sakurai F, Katayama K, Tashiro K, Matsui H, Kawabata K, et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 2011;17:2807-18.
21. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010;18:429-34.
22. Machitani M, Sakurai F, Wakabayashi K, Tomita K, Tachibana M, Mizuguchi H. Dicer functions as an antiviral system against human adenoviruses via cleavage of adenovirus-encoded noncoding RNA. Sci Rep 2016;6:27598.
23. Mizuguchi H, Kay MA, Hayakawa T. In vitro ligation-based cloning of foreign DNAs into the E3 and E1 deletion regions for generation of recombinant adenovirus vectors. Biotechniques 2001;30:1112-4, 6.
24. Motegi Y, Katayama K, Sakurai F, Kato T, Yamaguchi T, Matsui H, et al. An effective gene-knockdown using multiple shRNA-expressing adenovirus vectors. J Control Release 2011;153:149-53.
25. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998;9:2577-83.
26. Machitani M, Sakurai F, Katayama K, Tachibana M, Suzuki T, Matsui H, et al. Improving adenovirus vector-mediated RNAi efficiency by lacking the expression of virus-associated RNAs. Virus Res 2013;178:357-63.
27. Machitani M, Sakurai F, Wakabayashi K, Nakatani K, Shimizu K, Tachibana M, et al. NF-kappaB promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector. Sci Rep 2016;6:19922.
28. Wakabayashi K, Machitani M, Shimizu K, Tachibana M, Sakurai F, Mizuguchi H. Quantitative analysis of virus-associated RNAI expression following transduction with a replication-incompetent adenovirus vector in vitro and in vivo. J Mol Genet Med 2015;9:1000169.
29. Matsui H, Sakurai F, Katayama K, Abe Y, Machitani M, Kurachi S, et al. A targeted adenovirus vector displaying a human fibronectin type III domain-based monobody in a fiber protein. Biomaterials 2013;34:4191-201.
30. Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, et al. A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 2010;18:1123-9.
31. Rauschhuber C, Mueck-Haeusl M, Zhang W, Nettelbeck DM, Ehrhardt A. RNAi suppressor P19 can be broadly exploited for enhanced adenovirus replication and microRNA knockdown experiments. Sci Rep 2013;3:1363.
32. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 2009;119:3172-81.
33. Bennasser Y, Chable-Bessia C, Triboulet R, Gibbings D, Gwizdek C, Dargemont C, et al. Competition for XPO5 binding between Dicer mRNA, pre-miRNA and viral RNA regulates human Dicer levels. Nat Struct Mol Biol 2011;18:323-7.
34. Ostermann E, Tuddenham L, Macquin C, Alsaleh G, Schreiber-Becker J, Tanguy M, et al. Deregulation of type I IFN-dependent genes correlates with increased susceptibility to cytomegalovirus acute infection of dicer mutant mice. PLoS One 2012;7:e43744.
35. Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, et al. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 2007;27:123-34.
36. Yamaguchi T, Kawabata K, Kouyama E, Ishii KJ, Katayama K, Suzuki T, et al. Induction of type I interferon by adenovirus-encoded small RNAs. Proc Natl Acad Sci U S A 2010;107:17286-91.
37. Minamitani T, Iwakiri D, Takada K. Adenovirus virus-associated RNAs induce type I interferon expression through a RIG-I-mediated pathway. J Virol 2011;85:4035-40.